BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37773300)

  • 1. Evolution of predictive risk factor analysis for chemotherapy-related toxicity.
    Hertz DL; Lustberg MB; Sonis S
    Support Care Cancer; 2023 Sep; 31(10):601. PubMed ID: 37773300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Status of Immune Oncology: Challenges and Opportunities.
    Cesano A; Marincola FM; Thurin M
    Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology.
    Chen EI; Crew KD; Trivedi M; Awad D; Maurer M; Kalinsky K; Koller A; Patel P; Kim Kim J; Hershman DL
    PLoS One; 2015; 10(12):e0145816. PubMed ID: 26710119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer biomarker discovery and translation: proteomics and beyond.
    Hristova VA; Chan DW
    Expert Rev Proteomics; 2019 Feb; 16(2):93-103. PubMed ID: 30556752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies.
    Umelo IA; Costanza B; Castronovo V
    Cancer Metastasis Rev; 2018 Mar; 37(1):125-145. PubMed ID: 29392535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics: Driving Personalized Medicine.
    Sadee W; Wang D; Hartmann K; Toland AE
    Pharmacol Rev; 2023 Jul; 75(4):789-814. PubMed ID: 36927888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.
    Hertz DL
    Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):227-239. PubMed ID: 33401943
    [No Abstract]   [Full Text] [Related]  

  • 8. Power of proteomics and progress in precision medicine - 13th central and eastern European proteomic conference (CEEPC), Ustroń, Poland.
    Gadher SJ; Widlak P; Kovarova H
    Expert Rev Proteomics; 2020 May; 17(5):335-340. PubMed ID: 32510255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of individual response to anticancer therapy: historical and future perspectives.
    Unger FT; Witte I; David KA
    Cell Mol Life Sci; 2015 Feb; 72(4):729-57. PubMed ID: 25387856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-omics strategies for personalized and predictive medicine: past, current, and future translational opportunities.
    Ahmed Z
    Emerg Top Life Sci; 2022 Apr; 6(2):215-225. PubMed ID: 35234253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline Genetics in Immuno-oncology: From Genome-Wide to Targeted Biomarker Strategies.
    Kirchhoff T; Ferguson R
    Methods Mol Biol; 2020; 2055():93-117. PubMed ID: 31502148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of prognostic and predictive biomarkers in high-dimensional data with PPLasso.
    Zhu W; Lévy-Leduc C; Ternès N
    BMC Bioinformatics; 2023 Jan; 24(1):25. PubMed ID: 36690931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.
    Fu S; Liu X; Luo M; Xie K; Nice EC; Zhang H; Huang C
    Expert Rev Proteomics; 2017 Apr; 14(4):351-362. PubMed ID: 28276747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation.
    Alymani NA; Smith MD; Williams DJ; Petty RD
    Eur J Cancer; 2010 Mar; 46(5):869-79. PubMed ID: 20138504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass spectrometry based proteomics and metabolomics in personalized oncology.
    Kowalczyk T; Ciborowski M; Kisluk J; Kretowski A; Barbas C
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165690. PubMed ID: 31962175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning.
    Miao R; Chen HH; Dang Q; Xia LY; Yang ZY; He MF; Hao ZF; Liang Y
    Pharmacol Res; 2020 Sep; 159():104932. PubMed ID: 32473309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomics and metabolomics in biomarker discovery for cardiovascular diseases: progress and potential.
    Tuñón J; Barbas C; Blanco-Colio L; Burillo E; Lorenzo Ó; Martín-Ventura JL; Más S; Rupérez FJ; Egido J
    Expert Rev Proteomics; 2016 Sep; 13(9):857-71. PubMed ID: 27459711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic Predictors of Response.
    Hertz DL; Rae JM
    Adv Exp Med Biol; 2016; 882():191-215. PubMed ID: 26987536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.